PM-02 CONDITIONAL INACTIVATION OF SMARCB1 IN P0 PERMISSIVE MOUSE CELLS GENERATES RHABDOID TUMORS IN THE PERIPHERAL NERVOUS SYSTEM AND IN THE BRAIN

Por Vitte, Jeremie, Chareyre, Fabrice, Stemmer-Rachamimov, Anat, Judkins, Alexander, Giovannini, Marco
Publicado no Neuro Oncol (2015)

Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development

Por Vitte, Jeremie, Gao, Fuying, Coppola, Giovanni, Judkins, Alexander R., Giovannini, Marco
Publicado no Nat Commun (2017)

TMOD-15. SPATIOTEMPORAL LOSS OF SMARCB1 IN EARLY NEURAL CREST LINEAGE LEADS TO DIFFERENT MOLECULAR SUBTYPES OF RHABDOID TUMORS

Por Vitte, Jeremie, Gao, Fuying, Coppola, Giovanni, Judkins, Alexander R, Giovannini, Marco
Publicado no Neuro Oncol (2019)

Refined Characterization of the Expression and Stability of the SMN Gene Products

Por Vitte, Jérémie, Fassier, Coralie, Tiziano, Francesco D., Dalard, Cécile, Soave, Sabrina, Roblot, Natacha, Brahe, Christine, Saugier-Veber, Pascale, Bonnefont, Jean Paul, Melki, Judith
Publicado em 2007

Deletion of Murine Smn Exon 7 Directed to Liver Leads to Severe Defect of Liver Development Associated with Iron Overload

Por Vitte, Jérémie M., Davoult, Bénédicte, Roblot, Natacha, Mayer, Michèle, Joshi, Vandana, Courageot, Sabrina, Tronche, François, Vadrot, Jacqueline, Moreau, Marie Helene, Kemeny, François, Melki, Judith
Publicado em 2004

mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma

Por Giovannini, Marco, Bonne, Nicolas-Xavier, Vitte, Jeremie, Chareyre, Fabrice, Tanaka, Karo, Adams, Rocky, Fisher, Laurel M., Valeyrie-Allanore, Laurence, Wolkenstein, Pierre, Goutagny, Stephane, Kalamarides, Michel
Publicado em 2014

MODL-13. GENETICALLY ENGINEERED PIG MODEL OF RHABDOID TUMOR PREDISPOSITION SYNDROME-1

Por Na, Brian, Rubinstein, C Dustin, Meudt, Jennifer J, Biegel, Jaclyn A, Judkins, Alexander R, Lehman, Brent P, Reichert, Jamie L, Vitte, Jeremie, Shanmuganayagam, Dhanansayan, Giovannini, Marco
Publicado no Neuro Oncol (2020)

Rac1-mediated DNA damage and inflammation promote Nf2 tumorigenesis but also limit cell cycle progression

Por Shi, Yuhao, Bollam, Saumya R., White, Shannon M., Laughlin, Sean Z., Graham, Garrett T., Wadhwa, Mandheer, Chen, Hengye, Nguyen, Chan, Vitte, Jeremie, Giovannini, Marco, Toretsky, Jeffery, Yi, Chunling
Publicado no Dev Cell (2016)

Expanding the mutational spectrum of LZTR1 in schwannomatosis

Por Paganini, Irene, Chang, Vivian Y, Capone, Gabriele L, Vitte, Jeremie, Benelli, Matteo, Barbetti, Lorenzo, Sestini, Roberta, Trevisson, Eva, Hulsebos, Theo JM, Giovannini, Marco, Nelson, Stanley F, Papi, Laura
Publicado no Eur J Hum Genet (2015)

TMOD-23. PRECLINICAL DRUG EVALUATION IN A GENETICALLY ENGINEERED MINIPIG MODEL OF NEUROFIBROMATOSIS TYPE 1

Por Osum, Sara, Stemmer-Rachamimov, Anat, Widemann, Brigitte, Dombi, Eva, Vitte, Jeremie, Dahiya, Sonika, Rizvi, Tilat, Ratner, Nancy, Messiaen, Ludwine, Gutmann, David, Giovannini, Marco, Moertel, Christopher, Largaespada, David, Watson, Adrienne
Publicado no Neuro Oncol (2019)

Therapeutic Potential of HSP90 Inhibition for Neurofibromatosis Type 2

Por Tanaka, Karo, Eskin, Ascia, Chareyre, Fabrice, Jessen, Walter J., Manent, Jan, Niwa-Kawakita, Michiko, Chen, Ruihong, White, Cory H., Vitte, Jeremie, Jaffer, Zahara M., Nelson, Stanley F., Rubenstein, Allan E., Giovannini, Marco
Publicado no Clin Cancer Res (2013)

Update From the 2011 International Schwannomatosis Workshop: From Genetics to Diagnostic Criteria

Por Plotkin, Scott R., Blakeley, Jaishri O., Evans, D. Gareth, Hanemann, C. Oliver, Hulsebos, Theo J.M., Hunter-Schaedle, Kim, Kalpana, Ganjam V., Korf, Bruce, Messiaen, Ludwine, Papi, Laura, Ratner, Nancy, Sherman, Larry S., Smith, Miriam J., Stemmer-Rachamimov, Anat O., Vitte, Jeremie, Giovannini, Marco
Publicado em 2013

Parkin Deficiency Delays Motor Decline and Disease Manifestation in a Mouse Model of Synucleinopathy

Por Fournier, Margot, Vitte, Jérémie, Garrigue, Jérôme, Langui, Dominique, Dullin, Jean-Philippe, Saurini, Françoise, Hanoun, Naïma, Perez-Diaz, Fernando, Cornilleau, Fabien, Joubert, Chantal, Ardila-Osorio, Héctor, Traver, Sabine, Duchateau, René, Goujet-Zalc, Cécile, Paleologou, Katerina, Lashuel, Hilal A., Haass, Christian, Duyckaerts, Charles, Cohen-Salmon, Charles, Kahle, Philipp J., Hamon, Michel, Brice, Alexis, Corti, Olga
Publicado em 2009

Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1

Por Isakson, Sara H., Rizzardi, Anthony E., Coutts, Alexander W., Carlson, Daniel F., Kirstein, Mark N., Fisher, James, Vitte, Jeremie, Williams, Kyle B., Pluhar, G. Elizabeth, Dahiya, Sonika, Widemann, Brigitte C., Dombi, Eva, Rizvi, Tilat, Ratner, Nancy, Messiaen, Ludwine, Stemmer-Rachamimov, Anat O., Fahrenkrug, Scott C., Gutmann, David H., Giovannini, Marco, Moertel, Christopher L., Largaespada, David A., Watson, Adrienne L.
Publicado no Commun Biol (2018)

Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2–associated schwannomas reveals differences in efficacy and drug resistance development

Por Fuse, Marisa A, Dinh, Christine T, Vitte, Jeremie, Kirkpatrick, Joanna, Mindos, Thomas, Plati, Stephani Klingeman, Young, Juan I, Huang, Jie, Carlstedt, Annemarie, Franco, Maria Clara, Brnjos, Konstantin, Nagamoto, Jackson, Petrilli, Alejandra M, Copik, Alicja J, Soulakova, Julia N, Bracho, Olena, Yan, Denise, Mittal, Rahul, Shen, Rulong, Telischi, Fred F, Morrison, Helen, Giovannini, Marco, Liu, Xue-Zhong, Chang, Long-Sheng, Fernandez-Valle, Cristina
Publicado no Neuro Oncol (2019)